174 related articles for article (PubMed ID: 21329967)
1. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study.
Farley J; Sill MW; Birrer M; Walker J; Schilder RJ; Thigpen JT; Coleman RL; Miller BE; Rose PG; Lankes HA
Gynecol Oncol; 2011 May; 121(2):303-8. PubMed ID: 21329967
[TBL] [Abstract][Full Text] [Related]
2. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.
Burtness B; Goldwasser MA; Flood W; Mattar B; Forastiere AA;
J Clin Oncol; 2005 Dec; 23(34):8646-54. PubMed ID: 16314626
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
Santin AD; Sill MW; McMeekin DS; Leitao MM; Brown J; Sutton GP; Van Le L; Griffin P; Boardman CH
Gynecol Oncol; 2011 Sep; 122(3):495-500. PubMed ID: 21684583
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial.
Kurtz JE; Hardy-Bessard AC; Deslandres M; Lavau-Denes S; Largillier R; Roemer-Becuwe C; Weber B; Guillemet C; Paraiso D; Pujade-Lauraine E
Gynecol Oncol; 2009 Apr; 113(1):16-20. PubMed ID: 19232434
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study.
Secord AA; Blessing JA; Armstrong DK; Rodgers WH; Miner Z; Barnes MN; Lewandowski G; Mannel RS;
Gynecol Oncol; 2008 Mar; 108(3):493-9. PubMed ID: 18191993
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group.
Miller DS; Blessing JA; Ramondetta LM; Pham HQ; Tewari KS; Landrum LM; Brown J; Mannel RS
J Clin Oncol; 2014 Sep; 32(25):2744-9. PubMed ID: 25071133
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck.
Vermorken JB; Licitra L; Stöhlmacher-Williams J; Dietz A; Lopez-Picazo JM; Hamid O; Hossain AM; Chang SC; Gauler TC
Eur J Cancer; 2013 Sep; 49(13):2877-83. PubMed ID: 23726971
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.
Baselga J; Gómez P; Greil R; Braga S; Climent MA; Wardley AM; Kaufman B; Stemmer SM; Pêgo A; Chan A; Goeminne JC; Graas MP; Kennedy MJ; Ciruelos Gil EM; Schneeweiss A; Zubel A; Groos J; Melezínková H; Awada A
J Clin Oncol; 2013 Jul; 31(20):2586-92. PubMed ID: 23733761
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial.
Hitre E; Budai B; Takácsi-Nagy Z; Rubovszky G; Tóth E; Remenár É; Polgár C; Láng I
Br J Cancer; 2013 Sep; 109(5):1117-22. PubMed ID: 23942070
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.
Rosell R; Robinet G; Szczesna A; Ramlau R; Constenla M; Mennecier BC; Pfeifer W; O'Byrne KJ; Welte T; Kolb R; Pirker R; Chemaissani A; Perol M; Ranson MR; Ellis PA; Pilz K; Reck M
Ann Oncol; 2008 Feb; 19(2):362-9. PubMed ID: 17947225
[TBL] [Abstract][Full Text] [Related]
11. Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma.
Chen Y; Wu X; Bu S; He C; Wang W; Liu J; Guo W; Tan B; Wang Y; Wang J
Cancer Sci; 2012 Nov; 103(11):1979-84. PubMed ID: 22845557
[TBL] [Abstract][Full Text] [Related]
12. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
Pirker R; Pereira JR; von Pawel J; Krzakowski M; Ramlau R; Park K; de Marinis F; Eberhardt WE; Paz-Ares L; Störkel S; Schumacher KM; von Heydebreck A; Celik I; O'Byrne KJ
Lancet Oncol; 2012 Jan; 13(1):33-42. PubMed ID: 22056021
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer.
Schmid-Bindert G; Gebbia V; Mayer F; Arriola E; Márquez-Medina D; Syrigos K; Biesma B; Leschinger MI; Frimodt-Moller B; Ripoche V; Myrand SP; Nguyen TS; Hozak RR; Zimmermann A; Visseren-Grul C; Schuette W
Lung Cancer; 2013 Sep; 81(3):428-434. PubMed ID: 23790468
[TBL] [Abstract][Full Text] [Related]
14. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
[TBL] [Abstract][Full Text] [Related]
15. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of combined radiotherapy with EGFR inhibitors and chemotherapy for laryngeal organ preservation in patients with locally advanced hypopharyngeal carcinomas.
Zhang X; Wang J; Wu W; Liu M; Zhao F; Du L; Huang D; Yang S; Ma L
Curr Cancer Drug Targets; 2014; 14(6):589-98. PubMed ID: 25039274
[TBL] [Abstract][Full Text] [Related]
17. Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Vermorken JB; Mesia R; Rivera F; Remenar E; Kawecki A; Rottey S; Erfan J; Zabolotnyy D; Kienzer HR; Cupissol D; Peyrade F; Benasso M; Vynnychenko I; De Raucourt D; Bokemeyer C; Schueler A; Amellal N; Hitt R
N Engl J Med; 2008 Sep; 359(11):1116-27. PubMed ID: 18784101
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study.
Nezhat F; Wadler S; Muggia F; Mandeli J; Goldberg G; Rahaman J; Runowicz C; Murgo AJ; Gardner GJ
Gynecol Oncol; 2004 Apr; 93(1):144-8. PubMed ID: 15047228
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.
Herbst RS; Langer CJ
Semin Oncol; 2002 Feb; 29(1 Suppl 4):27-36. PubMed ID: 11894011
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.
Fiorica J; Holloway R; Ndubisi B; Orr J; Grendys E; Boothby R; DeCesare S; LaPolla J; Hoffman M; Patel J
Gynecol Oncol; 2002 Apr; 85(1):89-94. PubMed ID: 11925125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
